title: The potential application of iron chelators for the treatment of neurodegenerative diseases.
abstract: Many forms of neurodegenerative disease, for instance Alzheimer's disease, Parkinson's disease, Friedreich's ataxia, Hallervorden Spatz syndrome and macular degeneration, are associated with elevated levels of redox active metals in the brain and eye. A logical therapeutic approach therefore, is to remove the toxic levels of these metals, copper and iron in particular, by selective chelation. The increased number of iron-selective chelators now available for clinical use has enhanced interest in this type of therapy. This review summarises the recent developments in the design of chelators for treatment of neurodegenerative disease, identifies some of the essential properties for such molecules and suggests some future strategies.
authors.affiliation: King's College London, Institute of Pharmaceutical Science, Franklin-Wilkins Building, 150 Stamford Street, London, UKSE1 9NH.
authors.forename: Robert C
authors.initials: RC
authors.lastname: Hider
authors.forename: Sourav
authors.initials: S
authors.lastname: Roy
authors.forename: Yong Min
authors.initials: YM
authors.lastname: Ma
authors.forename: Xiao
authors.initials: X
authors.lastname: Le Kong
authors.forename: Jane
authors.initials: J
authors.lastname: Preston
mesh_terms: D000595:Amino Acid Sequence; D003300:Copper / Q000302:isolation & purification / Q000378:metabolism; D006801:Humans; D007501:Iron / Q000302:isolation & purification / Q000378:metabolism; D007502:Iron Chelating Agents / Q000008:administration & dosage / Q000737:chemistry* / Q000494:pharmacology / Q000627:therapeutic use*; D008958:Models, Molecular; D008969:Molecular Sequence Data; D019636:Neurodegenerative Diseases / Q000188:drug therapy*
chemical_list: D007502:Iron Chelating Agents; D003300:Copper; D007501:Iron